Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Bought by First Trust Direct Indexing L.P.

First Trust Direct Indexing L.P. boosted its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 23.4% during the 1st quarter, HoldingsChannel reports. The firm owned 4,981 shares of the medical research company’s stock after buying an additional 945 shares during the quarter. First Trust Direct Indexing L.P.’s holdings in Thermo Fisher Scientific were worth $2,895,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Sugarloaf Wealth Management LLC raised its holdings in shares of Thermo Fisher Scientific by 6.9% during the fourth quarter. Sugarloaf Wealth Management LLC now owns 294 shares of the medical research company’s stock worth $156,000 after acquiring an additional 19 shares in the last quarter. Rosenberg Matthew Hamilton grew its stake in shares of Thermo Fisher Scientific by 3.7% in the 4th quarter. Rosenberg Matthew Hamilton now owns 526 shares of the medical research company’s stock valued at $279,000 after buying an additional 19 shares in the last quarter. Tsfg LLC raised its position in Thermo Fisher Scientific by 8.3% during the fourth quarter. Tsfg LLC now owns 249 shares of the medical research company’s stock valued at $132,000 after acquiring an additional 19 shares in the last quarter. Pacifica Partners Inc. lifted its stake in Thermo Fisher Scientific by 16.5% in the fourth quarter. Pacifica Partners Inc. now owns 141 shares of the medical research company’s stock valued at $69,000 after acquiring an additional 20 shares during the last quarter. Finally, Foundations Investment Advisors LLC increased its stake in shares of Thermo Fisher Scientific by 1.9% during the 4th quarter. Foundations Investment Advisors LLC now owns 1,069 shares of the medical research company’s stock worth $591,000 after purchasing an additional 20 shares during the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Price Performance

Shares of NYSE TMO traded up $1.68 during mid-day trading on Thursday, hitting $535.61. 908,266 shares of the stock were exchanged, compared to its average volume of 1,717,972. Thermo Fisher Scientific Inc. has a twelve month low of $415.60 and a twelve month high of $603.82. The company has a market cap of $204.45 billion, a P/E ratio of 34.36, a PEG ratio of 2.49 and a beta of 0.77. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.33 and a current ratio of 1.70. The stock’s fifty day simple moving average is $573.05 and its two-hundred day simple moving average is $563.41.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, April 24th. The medical research company reported $5.11 EPS for the quarter, beating analysts’ consensus estimates of $4.70 by $0.41. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. The firm had revenue of $10.35 billion for the quarter, compared to analyst estimates of $10.14 billion. As a group, analysts forecast that Thermo Fisher Scientific Inc. will post 21.65 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, July 15th. Investors of record on Friday, June 14th will be paid a dividend of $0.39 per share. The ex-dividend date is Friday, June 14th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.29%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.01%.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on TMO shares. Deutsche Bank Aktiengesellschaft upped their price objective on shares of Thermo Fisher Scientific from $600.00 to $610.00 and gave the stock a “buy” rating in a report on Thursday, April 25th. Citigroup started coverage on Thermo Fisher Scientific in a research note on Monday, March 18th. They issued a “neutral” rating and a $620.00 price objective on the stock. Robert W. Baird lowered their price target on Thermo Fisher Scientific from $621.00 to $620.00 and set an “outperform” rating on the stock in a report on Thursday, April 25th. The Goldman Sachs Group boosted their price objective on shares of Thermo Fisher Scientific from $550.00 to $640.00 and gave the stock a “buy” rating in a research note on Wednesday, April 10th. Finally, Evercore ISI dropped their target price on shares of Thermo Fisher Scientific from $615.00 to $600.00 and set an “outperform” rating on the stock in a report on Tuesday. Five research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and an average target price of $606.47.

Insider Activity at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction that occurred on Tuesday, April 30th. The shares were sold at an average price of $572.41, for a total value of $5,724,100.00. Following the sale, the chief executive officer now directly owns 123,816 shares in the company, valued at approximately $70,873,516.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, SVP Michael A. Boxer sold 2,000 shares of the firm’s stock in a transaction on Friday, April 26th. The shares were sold at an average price of $567.94, for a total transaction of $1,135,880.00. Following the sale, the senior vice president now directly owns 13,083 shares in the company, valued at $7,430,359.02. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction on Tuesday, April 30th. The stock was sold at an average price of $572.41, for a total transaction of $5,724,100.00. Following the completion of the transaction, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at $70,873,516.56. The disclosure for this sale can be found here. Over the last quarter, insiders sold 22,000 shares of company stock worth $12,532,780. 0.34% of the stock is owned by insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.